<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921739</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00017361</org_study_id>
    <nct_id>NCT00921739</nct_id>
  </id_info>
  <brief_title>Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies</brief_title>
  <acronym>ESIMRT</acronym>
  <official_title>Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1- Using IMRT, the radiation therapy (RT) dose can be safely escalated from 58 Gy
      to 74 Gy given as 6 fractions/week with concurrent chemotherapy.

      Hypothesis 2- Esophageal motion can be used to customize planning organ at risk volumes.

      Hypothesis 3- Biological predictors of acute esophagitis can be used to identify patients at
      high risk of developing esophageal toxicity from radiation therapy and chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective phase I study designed to determine the maximum tolerated dose of radiation
      therapy given in an accelerated fashion (2 Gy/fraction, 6 fractions/week) with concurrent
      chemotherapy. Intensity-modulated radiation therapy (IMRT) will be utilized to spare the
      esophagus. All patients on the dose escalation study will participate in additional
      assessments evaluating esophageal motion and esophageal toxicity from radiation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of IMRT</measure>
    <time_frame>within 30 days of completing RT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of RT-induced acute esophagitis</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if biological predictors of esophagitis can identify patients who develop severe esophageal toxicity during radiation therapy</measure>
    <time_frame>Two years</time_frame>
    <description>Blood will be drawn at specific time intervals, plasma will be analysed for Glutathione Oxidation, Citrulline, Lipid peroxidation, DNA oxidation, and Tetrahydrobiopterin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Thymoma</condition>
  <condition>Thymus Neoplasms</condition>
  <arm_group>
    <arm_group_label>IMRT concurrent with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Esophageal sparing IMRT</intervention_name>
    <description>6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).</description>
    <arm_group_label>IMRT concurrent with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic documentation of one of the following thoracic malignancies:

               -  Non-small cell lung cancer (stage III or X (recurrent) with disease confined to
                  local/regional sites)

               -  Small cell lung cancer (stage II-III)

               -  Thymoma (unresectable)

               -  Thymic carcinoma (unresectable)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Weight loss &lt; 10% in preceding 3 months prior to diagnosis

          -  ANC &gt; or = 1500 and platelet count &gt; or = 100,000.

          -  Creatinine clearance greater than 50 ml/min

          -  18 years of age or older.

          -  Negative pregnancy test in women of child-bearing potential

        Exclusion Criteria:

          -  Prior thoracic irradiation

          -  Medical contraindications to thoracic irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Kelsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Dept Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001 Sep 1;92(5):1213-23.</citation>
    <PMID>11571735</PMID>
  </reference>
  <reference>
    <citation>Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11. Epub 2006 May 26.</citation>
    <PMID>16730134</PMID>
  </reference>
  <reference>
    <citation>Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler JW, Schaefer PL, Jett JR. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):370-8.</citation>
    <PMID>12243810</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Thymoma unresectable</keyword>
  <keyword>Thymic carcinoma unresectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

